TY  -  
T1  - Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras Mutant Lung Cancers 
SN  -  /  
UR  - http://hdl.handle.net/10138/306778 
T3  -  
A1  - Talwelkar, Sarang S.; Nagaraj, Ashwini S.; Devlin, Jennifer R.; Hemmes, Annabrita; Potdar, Swapnil; Kiss, Elina A.; Saharinen, Pipsa; Salmenkivi, Kaisa Maria; Mäyränpää, Mikko I.; Wennerberg, Krister; Verschuren, Emmy 
A2  -  
PB  -  
Y1  - 2019 
LA  - eng 
AB  - Most non-small cell lung cancers (NSCLC) contain nontargetable mutations, including KRAS, TP53, or STK11/LKB1 alterations. By coupling ex viva drug sensitivity profiling with in vivo drug response studies, we aimed to identify drug vulnerabilities for these NSCLC subtypes. Primary adenosquamous carcinoma (ASC) or adenocarcinoma (AC) cultures were established from Kras(G12D/+);Lkb1(fl/fl) (KL) tumors or AC cultures from Kras(G12D/+);p53(fl/fl) (KP) tumors. Although p53-null cells readily propagat... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - ADENOCARCINOMA; BIOLOGY; CARCINOMA; CONDITIONALLY REPROGRAMMED CELLS; DRIVEN; MEK INHIBITION; MODELS; RESISTANCE; STRATEGY; THERAPY; 3122 Cancers 
N1  -   
PP  -  
ER  -